Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL14485657 | 1.00 | ALOX15 (0.61) | ALOX15BLMPMP22KMT2AGRM8 | |
| Glutamine SCHEMBL25206739 | 0.94 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRM8 | |
| Glutamine SCHEMBL4615390 | 0.93 | ALOX15 (0.70) | ALOX15BLMPMP22KMT2AGRM8 | |
| Glutamine SCHEMBL4615387 | 0.93 | ALOX15 (0.70) | ALOX15BLMPMP22KMT2AGRM8 | |
| Glutamine SCHEMBL8082384 | 0.92 | ALOX15 (0.63) | ALOX15BLMPMP22KMT2AGRM8 | |
| Glutamine SCHEMBL8082387 | 0.92 | ALOX15 (0.63) | ALOX15BLMPMP22KMT2AGRM8 | |
| Glutamine SCHEMBL27791432 | 0.92 | ALOX15 (0.68) | ALOX15BLMPMP22KMT2AGRM8 | |
| Racemethionine SCHEMBL23361966 | 0.90 | BHMT (0.52) | ALOX15BLMPMP22KMT2AGRM8 | |
| Racemethionine SCHEMBL23361949 | 0.90 | BHMT (0.52) | ALOX15BLMPMP22KMT2AGRM8 | |
| Racemethionine SCHEMBL23648682 | 0.90 | BHMT (0.52) | ALOX15BLMPMP22KMT2AGRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688021-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2020-08-05 | — | — | EP | claimed |
| WO-2019067587-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-04-04 | — | — | WO | claimed |
| EP-3688021-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067587-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-04-04 | — | — | WO | disclosed |